MDACC Study No:2011-0951 ( NCT No: NCT01357161)
Title:A Randomized, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer
Principal Investigator:Robert Coleman
Treatment Agent:Carboplatin; MK-1775; Paclitaxel
Study Status:Closed
Study Description:The goal of this clinical research study is to compare MK-1775 in combination
with paclitaxel and carboplatin to placebo in combination with paclitaxel and
carboplatin in patients with ovarian cancer. Researchers want to learn if
adding MK-1775 can help to control the disease. The safety of this drug
combination will also be studied.

MK-1775 is designed to stop cancer cells from repairing themselves, which may
cause the cancer cells to die.

Paclitaxel and carboplatin are designed to block cancer cells from dividing,
which may cause them to die.

A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.
Hide details for General InformationGeneral Information

Disease Group:Ovary
Phase of Study:Phase II
Treatment Agents:Carboplatin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Merck
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Coleman
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-3357
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults